Adaptimmune Therapeutics PLC
ADAP0.055USD
0.000
交易中 （美東）報價延遲15分鐘
87.31M總市值
虧損本益比TTM
關於 Adaptimmune Therapeutics PLC 公司
Adaptimmune Therapeutics PLC 是一家臨牀階段的生物製藥公司。該公司專注於爲癌症患者提供細胞療法。其工程化 T 細胞受體 (TCR) 平臺能夠對 T 細胞進行工程化，以靶向和摧毀多種實體腫瘤類型的癌症。其細胞療法候選藥物包括 TCR T 細胞和 TruC T 細胞。其產品候選藥物包括 afamitresgene autoleucel (afami-cel) 和 Lete-cel。afamicel 是一種細胞療法，可爲滑膜肉瘤患者提供治療選擇。該公司正在過渡 lete-cel，該療法針對滑膜肉瘤和粘液樣圓細胞脂肪肉瘤 (MRCLS) 患者的 NY-ESO 抗原。其臨牀管線包括 ADP-A2M4CD8 的 SURPASS-III II 期試驗和 ADP-A2M4CD8 的 SURPASS I 期試驗。該公司最先進的臨牀前項目是針對 PRAME 靶點 (ADP-600) 和 CD70 (ADP-520) 的 T 細胞療法。ADAP-600 是一種工程化的 TCR T 細胞。
Adaptimmune Therapeutics PLC簡介
公司代碼ADAP
公司名稱Adaptimmune Therapeutics PLC
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
員工數量506
證券類型Depository Receipt
年結日May 06
公司地址60 Jubilee Avenue
城市ABINGDON
上市交易所NASDAQ Capital Market Consolidated
國家United Kingdom
郵編OX14 4RX
電話441235430000
網址https://www.adaptimmune.com/
公司代碼ADAP
上市日期May 06, 2015
CEOMr. Adrian Rawcliffe
Adaptimmune Therapeutics PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Andrew Allen, M.D., Ph.D.
Dr. Andrew Allen, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kristen M. Hege, M.D.
Dr. Kristen M. Hege, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
611.22K
+191.15%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Non-Executive Independent Director
Non-Executive Independent Director
23.89K
--
Mr. Christopher Hill
Mr. Christopher Hill
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Adrian Rawcliffe
Mr. Adrian Rawcliffe
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. William C. (Bill) Bertrand, Jr., Esq.
Mr. William C. (Bill) Bertrand, Jr., Esq.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. John P. Furey
Mr. John P. Furey
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 19 小時前
更新時間: 19 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
8.52%
EcoR1 Capital, LLC
4.15%
MPM Capital Inc.
1.81%
MPM BioImpact LLC
1.66%
其他
74.89%
持股股東
持股股東
佔比
Long Focus Capital Management LLC
8.96%
Two Seas Capital LP
8.52%
EcoR1 Capital, LLC
4.15%
MPM Capital Inc.
1.81%
MPM BioImpact LLC
1.66%
其他
74.89%
股東類型
持股股東
佔比
Hedge Fund
19.14%
Investment Advisor/Hedge Fund
9.14%
Research Firm
2.08%
Investment Advisor
0.98%
Individual Investor
0.63%
Pension Fund
0.07%
Venture Capital
0.03%
其他
67.94%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
177
83.31M
31.43%
-88.42M
2025Q2
192
118.54M
44.72%
-45.84M
2025Q1
196
118.11M
44.76%
-44.66M
2024Q4
195
128.66M
50.28%
-22.55M
2024Q3
199
155.41M
60.76%
-9.79M
2024Q2
202
157.35M
61.56%
-15.41M
2024Q1
213
165.17M
64.85%
-7.14M
2023Q4
210
146.11M
64.44%
-17.89M
2023Q3
229
151.45M
66.86%
-8.97M
2023Q2
226
147.93M
65.80%
+13.35M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Long Focus Capital Management LLC
23.76M
8.96%
--
--
Jun 30, 2025
Two Seas Capital LP
22.58M
8.52%
+2.05M
+9.99%
Jun 30, 2025
EcoR1 Capital, LLC
11.00M
4.15%
-16.40M
-59.86%
Aug 15, 2025
MPM Capital Inc.
4.81M
1.81%
-526.04K
-9.86%
Jun 30, 2025
MPM BioImpact LLC
4.41M
1.66%
-482.52K
-9.86%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.22M
1.59%
+1.59M
+60.49%
Jun 30, 2025
Rock Springs Capital Management LP
2.48M
0.94%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.96M
0.74%
-254.07K
-11.45%
Jun 30, 2025
Renaissance Technologies LLC
1.88M
0.71%
+69.00K
+3.80%
Jun 30, 2025
BofA Global Research (US)
1.14M
0.43%
-5.30K
-0.46%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12 小時前
更新時間: 12 小時前
機構名稱
佔比
ActivePassive International Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
SPDR S&P International Small Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ActivePassive International Equity ETF
佔比0%
Fidelity Enhanced Small Cap ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
